{"entity":{"id":"nct07100730","kind":"trial","name":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","aka":[],"tldr":"A phase 3 trial of TLX-101-Tx + Lomustine in glioma & glioblastoma, run by Telix Pharmaceuticals (Innovations) Pty Limited, now recruiting.","summary":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma is a phase 3 interventional study registered as NCT07100730 by Telix Pharmaceuticals (Innovations) Pty Limited, with 50 participants planned, started 2025-11-02 and due to reach its primary completion in 2027-07. Interventions recorded: TLX-101-Tx + Lomustine and TLX101-Tx.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07100730","url":"https://clinicaltrials.gov/study/NCT07100730"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07100730","phase":"3","setting":"A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients With Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX BrIGHT [IPAX-3])","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","enrolled":50,"outcomes":[]},"route":"/trials/nct07100730/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}